Downregulation of atrial markers during cardiac chamber morphogenesis is irreversible in murine embryos.
Vertebrate cardiogenesis is a complex process involving multiple, distinct tissue types which interact to form a four-chambered heart. Molecules have been identified whose expression patterns co-segregate with the maturation of the atrial and ventricular muscle cell lineages. It is not currently known what role intrinsic events versus external influences play in cardiac chamber morphogenesis. We developed novel, fluorescent-based, myocardial, cellular transplantation systems in order to study these questions in murine embryos and report the irreversible nature of chamber specification with respect to the downregulation of atrial myosin light chain 2 (MLC-2a) and alpha myosin heavy chain (alpha-MHC). Grafting ventricular cells into the atrial chamber does not result in upregulation of MLC-2a expression in ventricular cells. Additionally, wild-type ventricular muscle cells grafted into the wild-type background appropriately downregulate MLC-2a and alpha-MHC. Finally, grafting of RXRalpha gene-deficient ventricular muscle cells into the ventricular chambers of wild-type embryos does not rescue the persistent expression of MLC-2a, providing further evidence that ventricular chamber maturation is an early event. These studies provide a new approach for the mechanistic dissection of critical signaling events during cardiac chamber growth, maturation and morphogenesis in the mouse, and should find utility with other approaches of cellular transplantation in murine embryos. These experiments document the irreversible nature of the downregulation of atrial markers after the onset of cardiogenesis during ventricular chamber morphogenesis and temporally define the response of cardiac muscle cells to signals regulating chamber specification.
Gruber
P J
PJ
Department of Medicine, Center for Molecular Genetics, and the American Heart Association-Bugher Foundation Center for Molecular Biology, University of California, San Diego, La Jolla, California 92093-0613, USA.
Kubalak
S W
SW
Chien
K R
KR
D000818:Animals; D000943:Antigens, Differentiation; D017690:Cell Transplantation; D015536:Down-Regulation; D006325:Heart Atria / Q000166:cytology / Q000196:embryology*; D006352:Heart Ventricles / Q000166:cytology / Q000196:embryology*; D066298:In Vitro Techniques; D051379:Mice; D009024:Morphogenesis; D009206:Myocardium / Q000166:cytology; D018995:Myosin Heavy Chains / Q000096:biosynthesis*; D018994:Myosin Light Chains / Q000096:biosynthesis*; D018168:Receptors, Retinoic Acid / Q000172:deficiency / Q000235:genetics; D047488:Retinoid X Receptors; D014157:Transcription Factors / Q000172:deficiency / Q000235:genetics
D000943:Antigens, Differentiation; D018994:Myosin Light Chains; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D014157:Transcription Factors; D018995:Myosin Heavy Chains